A Phase 1 interventional study of Injectable semaglutide or injectable tirzepatide and Standard postoperative care in Obesity, Adolescent Obesity and Body-Weight Trajectory, sponsored by University of Colorado, Denver. Recruiting at 1 site in United States. Open to participants aged 12 Years to 24 Years. Per ClinicalTrials.gov, last updated 2026-07-15.
Sponsored by University of Colorado, Denver · Phase 1, Interventional, and Treatment
How we know · 4 judgments
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Pediatric Obesity by University of Colorado, Denver — 3 open to participants now, 5 under way, none of them phase 3. Pediatric Obesity · University of Colorado, Denver.
Among the 14 studies in Pediatric Obesity by University of Colorado, Denver, this one is the 9th largest by planned enrollment of the 11 interventional ones that give a count, is one of 2 that started in 2024, is the only one in phase 1, and was the 13th registered.
1,132 studies on the registry are indexed under Pediatric Obesity; 183 are open to participants now.
Browse Pediatric Obesity studies →3 of the 14 studies in Pediatric Obesity by University of Colorado, Denver are open now, in 1 country. Recruiting first, the newest first:
University of Colorado, Denver · Sites in United States
Ages 5–10 · Healthy volunteers
University of Colorado, Denver
Ages 5–99
By country, each count listing its studies:
Of the 119 Pediatric Obesity studies recruiting now, 16 (13%) set no upper age limit and 101 (85%) stop at 75 or younger; 110 take children under 18; 67 take healthy volunteers.
This study: 12 Years to 24 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 3 · Phase 3 2 · Phase 4 1
First in 2011; this study’s year is marked. 2 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 40 is below the median of 100 across 872 interventional studies indexed under Pediatric Obesity.
Median enrollment 100 across the 11 interventional studies, 57 across the 3 observational. Of the 9 that completed or were terminated, 4 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
University of Colorado, Denver is the lead sponsor of 1,547 studies on the registry; 318 are open to participants now.
Of its 148 completed or terminated interventional studies of FDA-regulated products, 93 (63%) have results posted.
2 of the studies in Pediatric Obesity by University of Colorado, Denver that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02669797University of Colorado, DenverFamily Matters Intervention | 2027-04 |
| NCT06575738University of Colorado, DenverPhysiologic Response to Bariatric Surgery and the Impact of Adjunct Semaglutide in Adolescents | 2027-09-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 14 studies in Pediatric Obesity by University of Colorado, Denver, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The study plans to learn more about what happens to the body after bariatric surgery in people 12 to 24 years old. The study aims to understand why people respond differently to bariatric surgery and how to define success beyond weight loss alone. The study also plans to learn more about whether a medication (semaglutide or tirzepatide) can help people 12 to 24 years old who, between 6 and 24 months after bariatric surgery, have not lost as much weight as expected.
1,132 studies on the registry are indexed under Pediatric Obesity; 183 are open to participants now.
This study's planned enrollment of 40 is below the median of 100 across 872 interventional studies indexed under Pediatric Obesity.
Browse Pediatric Obesity studies →University of Colorado, Denver is the lead sponsor of 1,547 studies on the registry; 318 are open to participants now.
Of its 148 completed or terminated interventional studies of FDA-regulated products, 93 (63%) have results posted.
Compared within Pediatric Obesity, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Obesity. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Observation Phase
Inclusion Criteria:
Exclusion Criteria:
Intervention/Treatment Phase
Inclusion Criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants complete a set of standardized measures before bariatric surgery, 3 months postoperatively, and 6 months postoperatively.
Participants can be enrolled between 6 and 24 months postoperatively and will receive usual interdisciplinary postoperative care plus weekly subcutaneous injectable semaglutide or tirzepatide for 26 weeks. Initial dose is 0.25mg (semaglutide) or 2.5mg (tirzepatide) and is escalated every 4 weeks as tolerated up to the max dose of 2.4mg for semaglutide or 15mg for tirzepatide for a total exposure of 26 weeks.
Drug: Injectable semaglutide or injectable tirzepatide · Behavioral: Standard postoperative care
Participants can be enrolled between 6 to 24 months postoperatively and will receive usual interdisciplinary postoperative care.
Behavioral: Standard postoperative care
Subcutaneous weekly injectable medication
Standard postoperative care consists of behaviorally-focused interventions delivered by the interdisciplinary Bariatric Surgery Center team targeting nutrition, physical activity, sleep, and mental health at standard postoperative intervals.
This study also gives SemaglutideStudies of SemaglutideSemaglutide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record., TirzepatideStudies of TirzepatideTirzepatide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.
Observational phase: Change in fasting glucagon-like peptide-1 (GLP1), measured by blood levels
GLP1 levels are measured prior to an oral mixed meal tolerance test
Time frame: Baseline, 6 months postoperatively
Observational phase: Change in stimulated glucagon-like peptide-1 (GLP1), measured by blood levels
GLP1 levels are measured during an oral mixed meal tolerance test
Time frame: Baseline, 6 months postoperatively
Observational phase: Change in insulin sensitivity (IS), measured by fasting blood insulin levels
Fasting insulin levels are measured. IS is defined as 1/fasting insulin
Time frame: Baseline, 6 months postoperatively
Observational phase: Change in percent fat free mass (FFM), measured by whole body dual-energy X-ray absorptiometry (DXA)
Percent FFM is calculated as (1-Percent Fat Mass) from DXA
Time frame: Baseline, 6 months postoperatively
Observational phase: Change in resting metabolic rate (RMR), measured by canopy indirect calorimetry
RMR from canopy indirect calorimetry
Time frame: Baseline, 6 months postoperatively
Observational phase: Change in 24 hour systolic blood pressure (BP), measured by ambulatory BP monitor
Mean 24 hour systolic BP
Time frame: Baseline, 6 months postoperatively
Observational phase: Change in indexed left ventricular mass (g/m to the 2.7th power), measured by echocardiogram
Resting supine 2-dimensional echocardiogram
Time frame: Baseline, 6 months postoperatively
Intervention phase: Change in BMI
\[(BMI at 26 weeks-Weight at Intervention Baseline)\]/(BMI at Intervention Baseline)\] \* 100
Time frame: Baseline, 26 weeks
Change in fasting glucagon-like peptide-1 (GLP1), measured by blood levels
GLP1 levels are measured prior to an oral mixed meal tolerance test
Time frame: Baseline, 3 months postoperatively
Change in stimulated glucagon-like peptide-1 (GLP1), measured by blood levels
GLP1 levels are measured during an oral mixed meal tolerance test
Time frame: Baseline, 3 months postoperatively
Change in fasting Peptide YY (PYY), measured by blood levels
PYY levels are measured prior to an oral mixed meal tolerance test
Time frame: Baseline, 3 months postoperatively
Change in fasting Peptide YY (PYY), measured by blood levels
PYY levels are measured prior to an oral mixed meal tolerance test
Time frame: Baseline, 6 months postoperatively
Change in stimulated Peptide YY (PYY), measured by blood levels
Plasma PYY levels are measured during an oral mixed meal tolerance test
Time frame: Baseline, 3 months postoperatively
Change in stimulated Peptide YY (PYY), measured by blood levels
Plasma PYY levels are measured during an oral mixed meal tolerance test
Time frame: Baseline, 6 months postoperatively
Change in fasting ghrelin, measured by blood levels
Ghrelin levels are measured prior to an oral mixed meal tolerance test
Time frame: Baseline, 3 months postoperatively
Change in fasting ghrelin, measured by blood levels
Ghrelin levels are measured prior to an oral mixed meal tolerance test
Time frame: Baseline, 6 months postoperatively
Change in stimulated ghrelin, measured by blood levels
Ghrelin levels are measured during an oral mixed meal tolerance test
Time frame: Baseline, 3 months postoperatively
Change in stimulated ghrelin, measured by blood levels
Ghrelin levels are measured during an oral mixed meal tolerance test
Time frame: Baseline, 6 months postoperatively
Change in insulin sensitivity (IS), measured by fasting blood insulin levels
Fasting insulin levels are measured. IS is defined as 1/fasting insulin
Time frame: Baseline, 3 months postoperatively
Change in percent fat free mass (FFM), measured by whole body dual-energy X-ray absorptiometry (DXA)
Percent FFM is calculated as (1-Percent Fat Mass) from DXA
Time frame: Baseline, 3 months postoperatively
Change in resting metabolic rate (RMR), measured by canopy indirect calorimetry
RMR from canopy indirect calorimetry
Time frame: Baseline, 3 months postoperatively
Change in 24 hour systolic blood pressure (BP), measured by ambulatory BP monitor
Mean 24 hour systolic BP
Time frame: Baseline, 3 months postoperatively
Change in indexed left ventricular mass (g/m to the 2.7th power), measured by echocardiogram
Resting supine 2-dimensional echocardiogram
Time frame: Baseline, 3 months postoperatively
Intervention Phase: Eligibility rate
(Patients meeting inclusion and exclusion criteria/Total patients screened)\*100
Time frame: Up to 150 weeks
Intervention Phase: Enrollment rate
(Participants enrolled/Patients eligible)\*100
Time frame: Up to 154 weeks
Intervention Phase: Retention rate
(Participants completing all intervention visits/Patients enrolled)\*100
Time frame: Up to 184 weeks
Intervention Phase: Mean maximum tolerated semaglutide dose or tirzepatide dose
Mean maximum tolerated dose (mg) of weekly injectable semaglutide or tirzepatide
Time frame: Baseline, 26 weeks
Intervention Phase: Number of participants with at least one serious adverse event (AE) in the active medication group, measured by a count
Individual participants with serious AEs will be counted
Time frame: Up to 30 weeks
Intervention Phase: Number of participants with an adverse event (AE) that leads to discontinuation of the medication, measured by a count
Participants experiencing an AE that leads to medication discontinuation will be counted
Time frame: Up to 30 weeks
Started Oct 2024 (actual). Primary completion is estimated for Sep 2027, 34 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Semaglutide · Tirzepatide
University of Colorado, Denver →